Severe cases of bleeding due to fibrinolytic agents are treated with
Rationale:
Severe cases of bleeding due to fibrinolytic agents are treated with EACA (Epsilon Amino Caproic Acid).
EACA is an antifibrinolytic that inhibits plasminogen activation, preventing fibrin degradation and stabilizing formed clots. This makes it the preferred treatment in bleeding caused by fibrinolytic drugs, which otherwise enhance clot breakdown and increase hemorrhage risk. EACA effectively counteracts excessive fibrinolysis, restoring hemostatic balance.
A: Aspirin reduces platelet aggregation but does not inhibit fibrinolysis, making it ineffective for bleeding from fibrinolytic agents.
B: Heparin is an anticoagulant enhancing antithrombin activity, which worsens bleeding by preventing clot formation rather than stopping fibrinolysis.
D: Vitamin K promotes synthesis of clotting factors but does not directly antagonize fibrinolytic activity or stabilize clots disrupted by fibrinolytic agents.
A patient to be commenced on oral anticoagulant therapy for DVT would be treated with: I. Oral anticoagulant therapy with warfarin for a goal international normalized ratio (INR) of 2-3 II. Oral anticoagulant therapy with warfarin for a goal INR of 2.5-3.5 III. Oral anticoagulant therapy with aspirin for a goal INR of 2-3
Rationale:
Oral anticoagulant therapy with warfarin for a goal international normalized ratio (INR) of 2-3 is the appropriate treatment for a patient commencing therapy for DVT. This INR range effectively balances preventing clot extension and minimizing bleeding risk. Warfarin is the standard oral anticoagulant, while aspirin does not achieve the necessary anticoagulation intensity for DVT management.
B: Oral anticoagulant therapy with aspirin for a goal INR of 2-3 lacks efficacy, as aspirin does not affect INR and provides insufficient anticoagulation to prevent deep vein thrombosis progression or recurrence.
C: Oral anticoagulant therapy with warfarin for a goal INR of 2.5-3.5 is not recommended because this higher INR range increases bleeding risk without additional benefit for standard DVT treatment.
D: Oral anticoagulant therapy with warfarin for an INR of 2.5-3.5 and aspirin combined is inappropriate; aspirin does not influence INR, and the higher INR target is unnecessarily elevated for typical DVT therapy.
A nurse receives instructions to monitor electrolyte levels and administer supplements as needed to an edematic patient taking Prednisone because
Rationale:
Prednisone requires monitoring of electrolyte levels and supplementation because concurrent use of potassium-depleting diuretics increases the risk of hypokalemia. Prednisone can cause potassium loss, and when combined with diuretics that also reduce potassium, the risk of dangerously low potassium levels rises, necessitating careful electrolyte management to prevent complications like cardiac arrhythmias and muscle weakness.
B: Concurrent use of NSAIDs increases the risk of hyperglycemia is inaccurate, as NSAIDs primarily affect kidney function and inflammation, not glucose metabolism or hyperglycemia associated with Prednisone.
C: Concurrent use of glucocorticoids and hypoglycemic agents potentiating electrolyte depletion misrepresents drug interactions, since hypoglycemic agents impact blood sugar, not electrolyte levels directly.
D: None of the above dismisses the known interaction between Prednisone and potassium-depleting diuretics, which is critical for patient safety and electrolyte balance.
Rather than being used for immediate effects, which of the following anti-inflammatory medications works gradually to promote decreased frequency and severity of exacerbations and acute asthma attacks?
Rationale:
Glucocorticoids work gradually to promote decreased frequency and severity of exacerbations and acute asthma attacks. They reduce airway inflammation over time, improving long-term asthma control rather than providing immediate relief. Their anti-inflammatory properties modify the underlying disease process, making them essential for preventing chronic symptoms and reducing the risk of severe asthma episodes with consistent use.
B: Methylxanthines primarily act as bronchodilators with mild anti-inflammatory effects but are not designed for gradual disease modification or prevention of exacerbations, focusing instead on immediate airway relaxation.
C: Inhaled anticholinergics mainly provide rapid bronchodilation by blocking muscarinic receptors, offering short-term symptom relief without addressing chronic inflammation or reducing exacerbation frequency.
D: This option incorrectly states glucocorticoids provide immediate effects, whereas their primary role is gradual inflammation reduction and long-term asthma management rather than instant symptom relief.
Which of the following is a correct combination of expected pharmacological action and therapeutic use of Inhaled anticholinergics like Ipratropium?
Rationale:
Inhaled anticholinergics like Ipratropium block muscarinic receptors of the bronchi, resulting in bronchodilation and are used to treat allergen-induced and exercise-induced bronchospasm. This mechanism reduces bronchial smooth muscle contraction by inhibiting parasympathetic stimulation, effectively relieving airway constriction in obstructive airway diseases such as asthma and COPD triggered by allergens or exercise.
B: Potentiates b2 adrenergic receptors of the bronchi, resulting in bronchoconstriction. This misstates the receptor type and effect; b2 adrenergic activation causes bronchodilation, not bronchoconstriction, and post-traumatic stress disease is unrelated.
C: Blocks a1 cholinergic receptors of the bronchi, resulting in bronchostimulation. Muscarinic receptors, not a1, mediate bronchial tone, and cholinergic receptors are not categorized as a1; bronchostimulation is not a therapeutic goal here.
D: Potentiates b1 cholinergic receptors of the bronchi, resulting in hyperpnea. b1 receptors are adrenergic, not cholinergic, and their activation does not directly influence bronchial tone or treat hypoxia effectively.
Patients who are being treated with epoetin alfa need to be monitored for the development of:
Rationale:
Patients treated with epoetin alfa need to be monitored for the development of hypertension. Epoetin alfa stimulates red blood cell production, which can increase blood viscosity and vascular resistance, leading to elevated blood pressure. Monitoring blood pressure is essential to prevent complications such as stroke or heart failure, ensuring safe and effective anemia management in patients receiving this therapy.
A: Thrombocytopenia involves low platelet counts, which epoetin alfa does not typically cause, as it primarily affects erythropoiesis rather than platelet production or destruction.
B: Neutropenia is a reduction in neutrophils, unrelated to epoetin alfa's mechanism, which targets red blood cell precursors, leaving white blood cell counts generally unaffected.
D: Gout results from uric acid accumulation, unrelated to epoetin alfa therapy, which does not influence purine metabolism or uric acid levels significantly.
A nurse caring for a 52-year-old patient who's been prescribed Hydrocodone for chronic back pain must observe for manifestations of
Rationale:
Respiratory depression (respirations less than 12/min) is a critical manifestation to monitor in patients prescribed Hydrocodone. Hydrocodone, an opioid analgesic, depresses the central nervous system, particularly respiratory centers, which can slow breathing rates dangerously. Early detection of respiratory depression ensures timely intervention, preventing life-threatening hypoxia and maintaining patient safety during opioid therapy.
B: Tachyarrhythmia (heartrate more than 100 bpm) is unrelated to Hydrocodone’s primary side effects, as opioids typically depress nervous system activity rather than causing elevated heart rates or arrhythmias.
C: Polyuria (urine output exceeding 3 L/day) does not commonly result from Hydrocodone use, since opioids primarily affect pain and respiratory systems, not renal function or urine production.
D: Polydipsia (water intake exceeding 6 L/day) is not associated with opioid administration, as Hydrocodone does not induce excessive thirst or fluid intake as a pharmacologic effect.
Platelet aggregation is an important event in haemostasis. Which of the following statement is true for platelet aggregation in vascular injury?
Rationale:
Platelets change their shape during the process of aggregation in vascular injury.
During platelet aggregation, platelets undergo morphological changes, transforming from a disc shape to a spiny form to increase surface area and promote adhesion. This shape change is critical for forming a stable platelet plug at the injury site, facilitating effective haemostasis by allowing stronger interactions among platelets and the damaged vessel wall.
A: There will be initial vasodilation Vasodilation does not occur initially; instead, vasoconstriction reduces blood flow to limit bleeding, making vasodilation an inaccurate description of the early haemostatic response.
B: Clotting factors play no role in its formation Clotting factors are essential in stabilizing the platelet plug by forming fibrin mesh, so they significantly contribute to aggregation and overall haemostasis.
D: Serotonin stimulates platelet aggregation Serotonin primarily causes vasoconstriction and enhances vascular tone, but it does not directly stimulate platelet aggregation during haemostasis.
A patient has had recent mechanical heart valve surgery and is receiving anticoagulant therapy. While monitoring the patient's laboratory work, the nurse interprets that the patient's international normalized ratio (INR) level of 3 indicates that:
Rationale:
An INR level of 3 indicates that the patient's warfarin dose is at therapeutic levels. Warfarin therapy aims to maintain an INR between 2 and 3 for mechanical heart valve patients to prevent clot formation effectively. An INR of 3 suggests adequate anticoagulation, balancing the risk of thrombosis and bleeding, affirming proper dosing and therapy management.
A: the patient's intravenous heparin dose is dangerously high. Heparin monitoring utilizes activated partial thromboplastin time (aPTT), not INR, making this statement unrelated to the INR value provided.
B: the patient is not receiving enough warfarin to have a therapeutic effect. An INR of 3 falls within the therapeutic range, indicating sufficient anticoagulation, not an inadequate warfarin dose.
D: the patient's intravenous heparin dose is at therapeutic levels. Heparin dosing effectiveness is monitored through aPTT, not INR, so this interpretation does not apply to the INR measurement given.
A nurse starting a heparin antidote IV drip for a patient exhibiting effects of anticoagulant toxicity must remember that the proper rate/dose for Protamine administration is
Rationale:
Protamine should be administered as a slow IV infusion, no faster than 20 mg/min or 50 mg in 10 minutes.
This rate minimizes adverse reactions like hypotension and anaphylaxis during heparin reversal. The slow infusion ensures controlled neutralization of anticoagulation, promoting patient safety and effective management of toxicity without overwhelming the cardiovascular system.
A: Fast IV, no slower than 90 mg/min or 110 mg in 50 min. This excessive speed risks severe hypotension and allergic reactions, exceeding safe infusion parameters.
C: Fast IV, no slower than 70 mg/min or 3 mg in 80 min. The dose and rate are inconsistent and insufficient for effective anticoagulant reversal.
D: Fast IV, no faster than 25 mg/min or 55 mg in 15 min. The rate is still too rapid compared to recommended slow infusion guidelines, increasing adverse event risk.
A patient is presented with fever, vomiting, hypotension and facial edema after his business trip back from Africa. Viral hemorrhagic fever is suspected in this patient. Which of the following family does the suspected virus belong to?
Rationale:
The suspected virus belongs to the Filovirus family. Filoviruses, including Ebola and Marburg viruses, are known to cause viral hemorrhagic fevers characterized by fever, vomiting, hypotension, and facial edema, especially in patients returning from Africa. These viruses are highly pathogenic and transmitted through contact with infected bodily fluids, matching the clinical presentation described in this patient.
B: Togavirus is associated primarily with arthropod-borne diseases like chikungunya and rubella, which do not typically cause hemorrhagic fever or the severe symptoms described here.
C: Adenavirus generally causes respiratory, ocular, or gastrointestinal infections but is not linked to viral hemorrhagic fever or the severe systemic signs observed in this case.
D: Bunyavirus includes some hemorrhagic fever viruses but is less commonly linked to African outbreaks presenting with these specific symptoms compared to Filovirus.
A patient is receiving heparin therapy as part of the treatment for a pulmonary embolism. The nurse monitors the results of which laboratory test to check the drug's effectiveness?
Rationale:
Heparin therapy effectiveness is monitored by the activated partial thromboplastin time (aPTT). The aPTT test measures the time it takes for blood to clot, specifically assessing the intrinsic and common coagulation pathways affected by heparin. Monitoring aPTT ensures therapeutic anticoagulation levels, preventing clot progression without causing excessive bleeding, making it the most appropriate laboratory test during heparin treatment for pulmonary embolism.
A: Prothrombin time/international normalized ratio (PT/INR) evaluates the extrinsic pathway and is primarily used to monitor warfarin therapy, not heparin, making it unsuitable for assessing heparin’s anticoagulant effect.
B: Bleeding times assess platelet function and vascular integrity rather than coagulation pathways targeted by heparin, so they do not provide relevant information on heparin’s effectiveness.
D: Vitamin K levels reflect nutritional status affecting warfarin therapy but do not influence heparin’s mechanism or its anticoagulant monitoring, rendering this test irrelevant for heparin treatment.
Spherocytosis is a common cause of inherited haemolytic anaemia. The most likely cause for spherocytosis is
Rationale:
Spherocytosis is most likely caused by defects in the peripheral proteins.
Defects in peripheral proteins such as spectrin, ankyrin, or band 4.2 disrupt the cytoskeletal network maintaining red blood cell shape, leading to spherical, less deformable cells prone to hemolysis. This structural instability causes the characteristic spherocytes seen in hereditary spherocytosis, directly linking peripheral protein defects to the disease pathology.
A: Abnormal antigenic properties of integral proteins affect immune recognition but do not cause spherocyte formation or membrane stability issues central to spherocytosis.
C: Increased formation of rolealux is unrelated to red blood cell morphology or hereditary membrane defects involved in spherocytosis.
D: Formation of sickle shaped cells pertains to sickle cell anemia, a distinct condition involving hemoglobin polymerization, not membrane protein defects.
Which of the following medications promotes increased cough production by increasing and thinning mucous secretions to allow patients to decrease chest congestion
Rationale:
Guaifenesin promotes increased cough production by increasing and thinning mucous secretions to help patients decrease chest congestion. This expectorant works by loosening mucus in the airways, making it easier to cough up and clear the respiratory tract, thereby alleviating congestion and improving breathing efficiency in patients experiencing mucus buildup.
B: Albuterol acts as a bronchodilator to relax airway muscles and ease breathing but does not affect mucus production or thinning, so it does not directly promote cough to clear chest congestion.
C: Hydrocodone is an opioid cough suppressant that reduces the cough reflex, decreasing cough frequency rather than increasing mucus clearance or thinning secretions.
D: All options cannot be correct since only guaifenesin increases and thins mucus to promote productive coughing; others serve different respiratory functions.
The following pathological features is true regarding non-Hodgkin lymphoma (NHL)
Rationale:
B: B cell phenotype is more common in non-Hodgkin lymphoma (NHL) because most NHL subtypes originate from B lymphocytes, reflecting their predominance in lymphoid tissue malignancies. This characteristic helps distinguish NHL from other lymphomas and guides immunophenotyping and treatment strategies, emphasizing the critical role of B cells in the disease’s pathology and clinical behavior.
A: Classical Reed Sternberg (RS) cells are hallmark of Hodgkin lymphoma, not NHL, making this feature specific to a different lymphoma subtype and irrelevant to NHL’s pathological identification.
C: Contiguous group of lymph nodes are typically involved in Hodgkin lymphoma, whereas NHL often affects non-contiguous lymph node groups, showcasing a distinct pattern of spread.
D: NHL frequently exhibits a leukemic phase, especially in aggressive or advanced cases, contradicting the statement that it is not associated with leukaemic phases of disease.
A patient is being discharged on anticoagulant therapy. The nurse will include in the patient education conversation that it is important to avoid herbal products that contain which substance?
Rationale:
Ginkgo should be avoided because it contains substances that can increase bleeding risk when combined with anticoagulants. Ginkgo’s antiplatelet effects potentiate anticoagulant therapy, raising the likelihood of hemorrhage. Patient education must emphasize avoiding such herbal products to prevent adverse bleeding events. This knowledge is crucial for safe medication management during anticoagulant therapy.
A: Valerian primarily affects sedation and does not significantly influence bleeding risk, making it less relevant in anticoagulant therapy education.
B: Saw palmetto is mainly associated with urinary symptoms and lacks significant anticoagulant or bleeding risk interactions.
C: Soy contains phytoestrogens without notable effects on coagulation, so it is not critical to avoid during anticoagulant use.
In case of heparin toxicity, which of the following medications can bind with heparin and form a heparin protamine complex that has no anticoagulant properties?
Rationale:
Heparin protamine complex formation without anticoagulant effects can be achieved by all listed administration methods: IV Push Protamine, IV Bolus Protamine, and IV Drip Protamine.
D: This choice encompasses all administration routes of protamine that effectively bind heparin to neutralize its activity, offering flexibility in clinical settings based on patient condition and urgency.
A: IV Push Protamine involves rapid injection but excludes slower infusion methods, limiting versatility in treatment approaches.
B: IV Bolus Protamine suggests a single large dose, which does not consider continuous infusion possibilities.
C: IV Drip Protamine implies gradual administration only, ignoring faster delivery options suitable in emergencies.
If a patient has an INR greater than 20 and active bleeding that is clinically significant (i.e., hematuria), the pharmacist should
Rationale:
The pharmacist should hold the drug therapy, administer vitamin K, and administer fresh frozen plasma. This approach addresses the dangerously high INR and active bleeding by stopping anticoagulation, reversing warfarin effects quickly with vitamin K, and replenishing clotting factors through fresh frozen plasma to control hemorrhage and reduce bleeding risk effectively.
A: Hold the drug therapy only neglects the urgent need for vitamin K and plasma to reverse coagulopathy and control bleeding, which are critical in managing INR above 20 with active hemorrhage.
C: Holding therapy and vitamin K without fresh frozen plasma omits essential clotting factor replacement, delaying reversal of bleeding in severe coagulopathy, risking patient safety due to insufficient hemostatic correction.
D: Administering vitamin K and fresh frozen plasma without holding drug therapy fails to stop ongoing anticoagulant effects, allowing continued INR elevation and bleeding risk despite partial reversal efforts.
The vector of visceral leishmaniasis has geographical variations. In the Asian region the main vector is
Rationale:
The main vector of visceral leishmaniasis in the Asian region is Phlebotamus species. Phlebotamus species are sandflies primarily responsible for transmitting Leishmania parasites in Asia, adapting well to the regional climate and ecological niches. Their distribution aligns closely with endemic areas, making them the principal vector for visceral leishmaniasis in this geographic zone.
B: Lutzomyia species predominantly transmit leishmaniasis in the Americas, not Asia, reflecting their ecological specialization in New World environments rather than the Old World regions like Asia.
C: Anopheles species are vectors of malaria, not leishmaniasis, as they transmit Plasmodium parasites, thus they do not contribute to visceral leishmaniasis transmission.
D: Mansonia species primarily serve as vectors for filarial parasites, not Leishmania, making them unrelated to the transmission of visceral leishmaniasis in any region.
Which of the following drugs are used in patients who have acute and chronic pulmonary disorders exacerbated by large amounts of secretions?
Rationale:
Mucolytics are used in patients with acute and chronic pulmonary disorders exacerbated by large amounts of secretions. Mucolytics work by breaking down mucus structure, reducing its viscosity, and facilitating easier clearance from the airways. This action helps alleviate airway obstruction caused by thick secretions, improving breathing and reducing infection risk in pulmonary conditions characterized by excessive mucus production.
B: Glucocorticoids primarily reduce inflammation rather than targeting mucus viscosity, so they do not directly address thick secretions in pulmonary disorders.
C: Beta adrenergic antagonists generally cause bronchoconstriction and do not facilitate mucus clearance, making them unsuitable for managing excessive respiratory secretions.
D: Antihistamines reduce allergic reactions but typically cause drying of secretions instead of breaking them down, which can worsen mucus clearance in pulmonary conditions.
A patient has been prescribed aspirin 320 mg per day for their atrial fibrillation. They also take aspirin four or more times a day for arthritis pain. What are the symptoms of aspirin toxicity for which they would need to be evaluated?
Rationale:
Aspirin toxicity commonly presents with tinnitus. This symptom occurs due to salicylate’s effect on the auditory system, indicating early signs of overdose. Monitoring for tinnitus helps detect toxicity promptly, preventing progression to more severe complications like metabolic acidosis or central nervous system effects. Thus, tinnitus is a key clinical marker warranting immediate medical evaluation in aspirin overdose cases.
B: Diarrhea is not a characteristic symptom of aspirin toxicity; gastrointestinal irritation may occur but diarrhea is uncommon and nonspecific, making it an unreliable indicator for salicylate overdose assessment.
C: Hearing loss may develop with chronic salicylate use but is generally a later manifestation, unlike tinnitus which is an early and more sensitive sign of aspirin toxicity requiring urgent attention.
D: Photosensitivity is unrelated to aspirin toxicity; it is typically associated with other medications such as tetracyclines or sulfonamides, thus not useful for identifying aspirin overdose symptoms.
Koilonychias is a specific feature of
Rationale:
Koilonychias is a specific feature of Iron deficiency anaemia.
Iron deficiency anaemia leads to koilonychia, characterized by spoon-shaped, thin, brittle nails due to inadequate iron affecting keratin synthesis. This distinctive nail deformity reflects chronic iron depletion impairing nail matrix function, differentiating it from other anaemias where such nail changes are uncommon or absent. It serves as a clinical clue for diagnosing iron deficiency.
A: Haemolytic anaemia involves increased red cell destruction without typical nail changes like koilonychia, making it unrelated to this specific feature.
B: Sickle cell disease causes abnormal hemoglobin and vaso-occlusive crises but does not produce the characteristic spoon-shaped nails seen in koilonychia.
C: Thalassaemia major results in severe anemia and bone changes, but koilonychia is not a commonly observed nail abnormality in this disorder.
Which of the following is false regarding heparin?
Rationale:
Heparin is not usually stored in the mast cells.
Heparin is primarily stored in the granules of mast cells and basophils, which is a known physiological fact, making option B false as it incorrectly states usual storage. This distinction is important for understanding heparin’s biological role and pharmacokinetics, highlighting why the statement contradicts accepted medical and biochemical knowledge about heparin distribution.
A: Subcutaneous heparin injection is avoided due to hematoma risk, reflecting clinical practice to prevent localized bleeding and bruising complications.
C: Heparin’s mechanism involves binding to antithrombin III, enhancing inhibition of activated thrombin, a critical anticoagulant action.
D: Protamine sulfate effectively neutralizes heparin overdose by binding and inactivating heparin molecules, reversing anticoagulant effects promptly.
A nurse treating chronic asthmatic patients with methylxanthines must remember to increase the dosage when prescribing this medication simultaneously with
Rationale:
Phenobarbital, phenytoin, and rifampin require an increased methylxanthine dosage when prescribed concurrently. These drugs induce hepatic enzymes, particularly CYP1A2, accelerating methylxanthine metabolism, lowering its plasma concentration, and reducing therapeutic effectiveness. Adjusting the dosage prevents subtherapeutic levels, ensuring adequate bronchodilation for chronic asthmatic patients. Close monitoring is essential to avoid treatment failure due to drug interactions affecting methylxanthine clearance.
A: Cimetidine, ciprofloxacin, and other fluoroquinolone antibiotics inhibit methylxanthine metabolism, causing increased plasma levels, which necessitates dosage reduction, not increase, to prevent toxicity.
C: Albuterol and TCAs do not significantly alter methylxanthine metabolism or clearance, thus no dosage adjustment is typically required when used concurrently.
D: Several drugs, including enzyme inducers, affect methylxanthine metabolism; claiming no risk ignores clinically relevant pharmacokinetic interactions requiring dosage modifications.
Monitoring for a patient prescribed iron for iron deficiency anemia includes:
Rationale:
Reticulocyte count one week after therapy is started is monitored to assess the bone marrow’s response to iron therapy, indicating effective erythropoiesis before changes in hemoglobin are evident. This early marker helps clinicians determine if iron supplementation is stimulating red blood cell production, guiding ongoing treatment decisions and ensuring timely intervention for iron deficiency anemia management.
B: Complete blood count every two weeks throughout therapy provides useful data but is less sensitive initially than reticulocyte count, delaying early detection of marrow response and treatment efficacy during the crucial first week.
C: Hemoglobin level at one week of therapy changes too slowly to reflect immediate bone marrow response, making it a delayed indicator compared to reticulocyte count for assessing treatment success.
D: INR weekly throughout therapy monitors coagulation status unrelated to iron deficiency anemia treatment, thus offering no relevant information about iron therapy effectiveness or anemia improvement.
A 40 year old patient is presented with unilateral palpebral edema and ipsilateral lymphadenopathy. He later develops megaesophagus and megacolon as complications. Which of the following vector is responsible for this parasitic infection?
Rationale:
The vector responsible for this parasitic infection is Rhodnius prolixus. This triatomine bug transmits Trypanosoma cruzi, the causative agent of Chagas disease, characterized by unilateral palpebral edema (Romaña’s sign), lymphadenopathy, and chronic complications like megaesophagus and megacolon due to autonomic nervous system damage in affected organs.
A: Glossina morsitans Transmits Trypanosoma brucei, causing African sleeping sickness, which presents with neurological symptoms rather than gastrointestinal megasyndromes or unilateral eyelid edema.
B: Ixodes scapularis This tick spreads Borrelia burgdorferi, responsible for Lyme disease, which primarily involves joint, skin, and neurologic symptoms but not megaesophagus or unilateral palpebral swelling.
D: Simulium damnosum This blackfly transmits Onchocerca volvulus, causing river blindness; its pathology involves skin and ocular lesions, not lymphadenopathy, unilateral palpebral edema, or gastrointestinal megacolon.
A nurse is reinforcing teaching with a client who is going to take an expectorant to manage a cough. The nurse should explain that this type of medication treats coughs by which of the following mechanisms?
Rationale:
Expectorants treat coughs by stimulating secretions, which helps thin mucus and makes it easier to expel from the respiratory tract. This mechanism facilitates clearing the airways, reducing congestion, and improving breathing comfort.
A: Reduces inflammation targets swelling and irritation but does not directly aid mucus clearance, so it does not describe expectorants’ primary function in cough treatment.
B: Suppresses the urge to cough involves antitussives that block cough reflex rather than enhancing mucus flow, differing fundamentally from expectorants’ way of action.
C: Dries mucous membranes decreases secretions, potentially thickening mucus and impairing clearance, which contrasts with expectorants that increase fluid secretions to ease cough effectiveness.
In the laboratory diagnosis of leishmaniasis, the expected parasite stage in vitro is
Rationale:
The expected parasite stage in vitro for leishmaniasis diagnosis is the promastigote.
Promastigotes are the motile, flagellated form of Leishmania that develop in culture media outside the host. This stage is crucial for laboratory identification, as amastigotes transform into promastigotes in vitro, enabling easier microscopic observation and confirmation of the parasite's presence.
A: Amastigote Amastigotes are intracellular, non-flagellated forms found within host macrophages, not typically cultured or observed in vitro for diagnostic purposes.
C: Trypamastigote Trypomastigotes belong to Trypanosoma species, not Leishmania, making them irrelevant for leishmaniasis diagnosis.
D: Schizont Schizonts are a developmental stage of Plasmodium species, unrelated to Leishmania, and thus not seen or used in leishmaniasis diagnosis.
A 36 year old woman presented with weakness, lassitude and feeling easily tired. Her bone marrow aspirate showed 15% myeloblasts and reduced erythropoiesis. The most likely cause is
Rationale:
Acute myeloid leukaemia best explains the patient's symptoms and bone marrow findings. The presence of 15% myeloblasts, along with reduced erythropoiesis, indicates an acute proliferation of myeloid precursors, leading to marrow failure and anemia symptoms. These features align with AML, characterized by rapid onset of marrow infiltration by immature myeloid cells causing weakness and fatigue.
B: Acute lymphoid leukaemia primarily involves lymphoid precursors, not myeloblasts, making it inconsistent with the 15% myeloblasts and reduced erythropoiesis seen here. It typically presents with lymphoid lineage markers and different marrow morphology.
C: Myelofibrosis features marrow fibrosis and extramedullary hematopoiesis, not increased myeloblasts. It commonly shows marrow fibrosis rather than blasts proliferation, making it an unlikely cause of 15% myeloblasts.
D: Myelodysplastic syndrome involves ineffective hematopoiesis with dysplasia but usually less than 20% blasts; 15% blasts suggest progression but AML fits better due to acute presentation and blast percentage.
The first laboratory value indication that vitamin B12 therapy is adequately treating pernicious anemia is:
Rationale:
Reticulocyte count begins to rise.
Reticulocyte count rises first as it indicates the bone marrow’s response to vitamin B12 therapy by producing new red blood cells. This early increase precedes normalization of hemoglobin or hematocrit, reflecting effective treatment before full correction of anemia is observed. It is a sensitive and timely marker of hematologic recovery in pernicious anemia management.
A: Hematocrit levels start to rise. Hematocrit changes occur later, following reticulocyte increase, as it measures the proportion of red blood cells, not immediate bone marrow activity.
B: Hemoglobin levels return to normal. Hemoglobin normalization is delayed since it reflects overall red blood cell content, lagging behind early reticulocyte production after therapy initiation.
D: Vitamin B12 levels return to normal. Vitamin B12 levels may normalize quickly but do not indicate marrow response or anemia improvement, only biochemical replenishment.